Orforglipron2212020-52-3 99%Purity

Orforglipron is the first oral small-molecule GLP-1 receptor agonist to successfully complete a Phase 3 clinical trial. It can be administered at any time of day without dietary or water intake restrictions, offering greater convenience for patients and potentially improving medication adherence compared to injectable GLP-1 formulations.

As a pioneering agent in oral GLP-1 drug development, Orforglipron is poised to be the first in its class to receive regulatory approval, positioning it to capture substantial market share. In the pivotal Phase 3 ACHIEVE-1 trial, Orforglipron demonstrated robust efficacy across all dose groups, with reductions in glycated hemoglobin (HbA1c) ranging from 1.3% to 1.6%. At the highest once-daily dose, participants achieved an average weight loss of 7.3 kg, representing a 7.9% reduction in body weight. The overall safety and tolerability profile of Orforglipron was consistent with that of injectable GLP-1 receptor agonists, supporting its clinical utility.

The compound patent for Orforglipron is set to expire in May 2039.